Business
OncBioMune Provides Update on Phase 2 Clinical Trials of ProscaVax for Prostate Cancer
OncBioMune Provides Update on Phase 2 Clinical Trials of ProscaVax for Prostate Cancer.
About this update from Theralink Technologies Inc.
[{"type":"text","content":"\nOncBioMune Provides Update on Phase 2 Clinical Trials of ProscaVax for Prostate Cancer\n\nOncBioMune Provides Update on Phase 2 Clinical Trials of ProscaVax for Prostate Cancer\n\n\n BATON ROUGE, LA--(Marketwired - May 11, 2016) - OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) (\"OncBioMune\" or the \"Company\"), a clinical stage biopharmaceutical company engaged in the development of novel cancer products and a proprietary vaccine technology, today provides shareholders with an update on the clinical advancement of ProscaVax, the Company's novel cancer vaccine in development for prostate cancer.In the United States, a Phase 1a/1b trial of ProscaVax is ongoing at the Veterans' Administration Medical Center and the University of California San Diego Medical School, both in La Jolla, California. 16 of 20 patients have been enrolled in the 1a portion of the study with clinical data analyzed on 12 patients so far. Data to date shows ProscaVax to have a meaningful impact in reducing the rise in PSA (prostate specific antigen) levels in 60% (6 out of 10) of patients receiving six vaccinations and an increased immune response in 89% (8 out of 9) patients at 31 weeks after administration of the vaccine. No ProscaVax-related adverse events have occurred during the trial, matching the results from prior studies of ProscaVax and other vaccines built upon the vaccine platform. As previously disclosed, the data is compelling enough that OncBioMune has elected to forego the Phase 1b component and advance ProscaVax into two, separate Phase 2 studies.The Company is preparing to initiate one of the Phase 2 trials at one of the world's leading university hospital networks located in the Northeast U.S. The trial will enroll patients at presentation of prostate cancer, a time where there are currently no therapeutic options other than surgery or radiation therapies, both of which have well documented morbidity issues. To the best of the Company's knowledge, ProscaVax will be the only cancer vaccine in the world in mid-stage clinical research evaluating safety and efficacy in prostate cancer patients in the \"active surveillance\" category.The trial protocol was submitted to the Principal Investigator of the trial, Dr. Glenn J. Bubley, Director of Genitourinary Oncology at Beth Israel Deaconess Medical Center, last week for review. Dr. Bubley has ...